Choose a language and wait for the translated text.
Under the deal with Jiangsu Alphamab is also eligible for development and commercialization milestone payments that, together with the upfront payment, could bring the deal's total value to as much as $2.09 billion, Alphamab Oncology said in a filing to the Hong Kong stock exchange.
Pathos AI to license experimental breast cancer drug from China's Jiangsu Alphamab Biopharmaceutical | PharmaVoice
